In this biography
Quick facts
- Born
- 16 March 1953
- Birthplace
- India; exact birthplace not established by the selected institutional records
- Country
- India
- Nationality
- Indian
- Known for
- Developing the Patel family’s pharmaceutical business after the 1995 Cadila restructuring
- Qualification
- Master of Pharmacy
- Cadila restructuring
- 1995
- Listed company renamed
- Zydus Lifesciences, February 2022
Why this life matters
His career helps distinguish an inherited pharmaceutical enterprise, its later corporate separation and the continuing work required to develop a research and manufacturing organisation.
Timeline
Key moments
Joins Cadila
Enters the pharmaceutical business founded by the previous generation.
Separate enterprise
Cadila Healthcare develops under the Patel family after the split from the Modi family.
Public capital and expansion
The listed enterprise adds brands, overseas businesses, manufacturing partnerships and research.
Zydus name and institutional role
Cadila Healthcare becomes Zydus Lifesciences; Patel becomes IIM Ahmedabad board chairperson later that year.
A pharmacy education and a family predecessor
Patel was born on 16 March 1953. He studied pharmacy and joined Cadila in 1976. His father Ramanbhai Patel had helped establish Cadila Laboratories with Indravadan Modi in 1952, giving the younger Patel an existing industrial and scientific setting in which to learn.
Forbes’s profile describes early responsibility for a plant producing pharmaceutical ingredients. This was practical manufacturing work within a family enterprise, not simply the inheritance of a chairman’s title. Production, research, selling and finance were distinct skills that the expanding company needed to coordinate.
1995 created a new organisational problem
The Patel and Modi families separated the business in 1995. Cadila Healthcare developed under the Patels and the Zydus identity, while Cadila Pharmaceuticals continued as a distinct Modi-family business. Both companies could refer to earlier Cadila origins, but their subsequent activities should not be merged into a single corporate record.
Patel’s later account emphasises organising the people who joined the restructured business. He described creating responsibilities and growth opportunities rather than treating inherited staff as an administrative burden. The testimony explains his management approach; it is one participant’s retrospective view, compared here with formal company records and independent reporting.
Financing and partnerships supported expansion
The company’s public listing in 2000 and later acquisitions supported a broader business. Forbes describes German Remedies and smaller overseas purchases, alongside manufacturing collaborations. Such transactions added brands, technical relationships or market access; they were not all purchases of the same kind of asset.
Research and contract manufacturing also developed together. A pharmaceutical group can sell established products while investing in new molecules, vaccines or biologics, but each activity has its own development and regulatory requirements. Patel’s chairmanship should not be turned into a claim that he personally invented every product produced by teams of scientists.
A name change did not merge the two Cadilas
On 24 February 2022 the listed Cadila Healthcare became Zydus Lifesciences. The announcement identifies Pankaj as chairman and Sharvil Patel as managing director. It presented the change as a common Zydus identity for a business that had already developed under that group name since the restructuring.
This was not the creation of the earlier Cadila Laboratories, nor the renaming of Cadila Pharmaceuticals. Checking the legal company matters when reading an approval, factory notice, acquisition or controversy. Similar names and a shared historical ancestor do not make the later companies interchangeable.
Corporate oversight and wider institutions
The reviewed Zydus director profile classifies Patel as non-executive chairman. It distinguishes board oversight from Sharvil Patel’s executive managing-director office. Institutional biographies also record his work with education, cancer-care and charitable organisations, and IIM Ahmedabad identifies him as board chairperson from November 2022.
A March 2026 IIMA report places him at the launch of a new artificial-intelligence school in that capacity. These assignments show a wider institutional career without establishing the outcomes of every programme. His 2025 Padma Bhushan recognises his public contribution, while business and research claims still require their own evidence.
Quick answers
Frequently asked questions about Pankaj Patel
- Are Zydus Lifesciences and Cadila Pharmaceuticals the same company?
- No. They developed separately after the 1995 restructuring. Zydus Lifesciences is the later name of Cadila Healthcare.
- Did Pankaj Patel found the original Cadila business?
- No. Ramanbhai Patel and Indravadan Modi established its predecessor in 1952. Pankaj joined in 1976 and led the later Zydus development.
- Is Patel the current managing director?
- The selected company records identify Pankaj Patel as non-executive chairman and Sharvil Patel as managing director.
Keep exploring
Lives connected to this story
- Kiran Mazumdar-Shaw
Compare the development of pharmaceutical manufacturing and research with Biocon’s biotechnology history.
- Harsh Mariwala
Compare two reorganisations that gave an existing family business a distinct operating identity.
Sources and further reading
Explore the evidence
These references support the biography and offer further reading. Official records, first-person accounts and independent reporting provide different perspectives; image records document attribution and licensing.
- 1. Zydus LifesciencesDirector profile: 16 March 1953 birth, MPharm, 1995 appointment and non-executive chairmanship
- 2. UK Companies HousePankaj Patel: Indian nationality and March 1953 birth month
- 3. Zydus LifesciencesMemorandum and Articles: 1995 subscribers, Ramanbhai and Pankaj Patel
Formal subscriber records support the 1995 legal enterprise; the predecessor’s 1952 origins and the 2022 rename are separate milestones. Exact birthplace is withheld.
- 4. Indian Pharmaceutical Alliance2025 industry history: Ramanbhai Patel, 1952 origins and 1995 restructuring
- 5. Cadila PharmaceuticalsHeritage: Modi family history and distinct 1995 restructuring
- 6. Forbes / Naazneen KarmaliDark Horse, June 2010: education, 1976 entry, split, organisation and financing
The 2010 report supplies attributed early-career and financing detail; it is not a source for present titles, valuations or medical efficacy.
- 7. Business TodayPankaj Patel’s account of organising people after the 1995 split, September 2012 issue
- 8. Zydus LifesciencesCadila Healthcare Limited is now Zydus Lifesciences Limited, 24 February 2022
- 9. IIM Ahmedabad ArchivesPankaj R. Patel: chairperson from November 2022, institutional and charitable roles
- 10. IIM Ahmedabad / The Indian ExpressMarch 2026 school launch: Pankaj Patel as board chairperson
- 11. Zydus LifesciencesJanuary 2025: Pankaj R. Patel, Zydus chairman, receives the Padma Bhushan
- 12. President’s Secretariat / Wikimedia CommonsComplete PIB 182571 award photograph and official source
The official caption names Pankaj R. Patel. Zydus’s primary 2025 award release identifies its chairman as the recipient; the complete official frame is retained rather than the cropped derivative.
- 13. Press Information BureauPrimary accurate-reproduction permission
